Literature DB >> 2920585

Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level.

P B Rock1, T S Johnson, R F Larsen, C S Fulco, L A Trad, A Cymerman.   

Abstract

Rapid exposure of unacclimatized persons to high altitude causes the syndrome acute mountain sickness (AMS). Prophylactic treatment with frequent high doses of dexamethasone has been shown to prevent AMS. To determine whether lower, less frequent doses were effective in preventing AMS, 28 men between the ages of 18 and 32 were exposed to a simulated altitude of 4,570 m for 45 h in a hypobaric chamber on two occasions while taking one of three doses of dexamethasone (4 mg, 1 mg, or .25 mg every 12 h) or a placebo in a double-blind, crossover design. The 4-mg dose of dexamethasone reduced the incidence of AMS symptoms compared with placebo and the other dose levels. Dexamethasone did not alter fluid balance or plasma volume changes, but treatment with 1 mg and 4 mg suppressed cortisol secretion. There was no evidence of adrenal cortical suppression after treatment with dexamethasone or placebo 48 h after discontinuing altitude exposure and drug treatment. The results indicate that 4 mg of dexamethasone twice daily is an effective prophylactic treatment for AMS, while lower doses are relatively ineffective.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920585     DOI: 10.1378/chest.95.3.568

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial.

Authors:  H R Keller; M Maggiorini; P Bärtsch; O Oelz
Journal:  BMJ       Date:  1995-05-13

Review 2.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

Review 3.  Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.

Authors:  L Dumont; C Mardirosoff; M R Tramèr
Journal:  BMJ       Date:  2000-07-29

4.  Safety of commercial airflight in patients with brain tumors: a case series.

Authors:  Michelle Phillips; Marlon Saria; Amy Eisenberg; Daniel F Kelly; Garni Barkhoudarian
Journal:  J Neurooncol       Date:  2018-05-17       Impact factor: 4.130

5.  Reprogramming of glucocorticoid receptor function by hypoxia.

Authors:  Tineke Vanderhaeghen; Steven Timmermans; Deepika Watts; Ville Paakinaho; Melanie Eggermont; Jolien Vandewalle; Charlotte Wallaeys; Lise Van Wyngene; Kelly Van Looveren; Louise Nuyttens; Sylviane Dewaele; Joke Vanden Berghe; Kelly Lemeire; Joey De Backer; Laura Dirkx; Wim Vanden Berghe; Guy Caljon; Bart Ghesquière; Karolien De Bosscher; Ben Wielockx; Jorma J Palvimo; Rudi Beyaert; Claude Libert
Journal:  EMBO Rep       Date:  2021-10-26       Impact factor: 8.807

Review 6.  Efficacy of ibuprofen on prevention of high altitude headache: A systematic review and meta-analysis.

Authors:  Juan Xiong; Hui Lu; Rong Wang; Zhengping Jia
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

7.  Efficacy and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials.

Authors:  Gaurav Nepal; Jayant Kumar Yadav; Jessica Holly Rehrig; Niroj Bhandari; Santosh Baniya; Rakesh Ghimire; Narayan Mahotra
Journal:  BMC Emerg Med       Date:  2020-05-13

8.  Effect of Acetazolamide and Zoledronate on Simulated High Altitude-Induced Bone Loss.

Authors:  Mikkel Bo Brent; Ulf Simonsen; Jesper Skovhus Thomsen; Annemarie Brüel
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

9.  Inflammatory gene expression during acute high-altitude exposure.

Authors:  Kathy Pham; Shyleen Frost; Keval Parikh; Nikhil Puvvula; Britney Oeung; Erica C Heinrich
Journal:  J Physiol       Date:  2022-08-17       Impact factor: 6.228

Review 10.  Bidirectional Crosstalk Between Hypoxia Inducible Factors and Glucocorticoid Signalling in Health and Disease.

Authors:  Tineke Vanderhaeghen; Rudi Beyaert; Claude Libert
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.